Hesheng Technology
合生科技
Hesheng Technology (合生科技) is a synthetic biology company founded by Tiangang Liu, who serves as its CEO and chief scientist while holding a distinguished professorship at Shanghai Jiao Tong University's School of Life Sciences and Biotechnology . FreeS Fund (峰瑞资本) backed the company at the pre-A round and continued to invest in its subsequent A round in early 2023, citing continued confidence in its future . The firm sits within FreeS's broader biotech portfolio alongside companies such as Bluepha Microbiology and Xiruan Technology . In a 2026 panel discussion, FreeS partner Rui Ma grouped Hesheng among its portfolio companies at the intersection of AI and science, indicating the fund's sustained involvement .
AI-generated — may contain errors, please verify.
Coverage
Has the Inflection Point for AI for Science Arrived?
Where will the next Nobel Prize emerge?
Has the Inflection Point for AI for Science Arrived?
Where will the next Nobel Prize emerge?
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
Biomanufacturing: Who Can Move Faster on the New Research Paradigm?
A Conversation with Professor Liu Tiangang on Future Industries: Biomanufacturing
Setting Off in Spring: 7 Early-Stage Companies Raise Over 800 Million | FreeS Family Funding News · Vol 14
Looking forward to working with more outstanding founders.
How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
The U.S.-China Biotech Race: Where Are the Opportunities in Synthetic Biology? | FreeS Fund Dialogue
Over the next five to ten years, which technologies will have a significant impact on synthetic biology?
